Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine ...

UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by ...

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class ...

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...

Early-stage cancer immunotherapy represents a promising yet underexplored frontier in cancer research. While immunotherapeutic strategies have achieved ...

Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

GSK plc has received Orphan Drug Designation in Japan for its investigational antibody-drug conjugate risvutatug rezetecan (Ris-Rez) for the treatment of small-cell lung cancer, supported by early ...